Research Paper Volume 15, Issue 9 pp 3498—3523

Figure 7. The MethScore predicts responses to immunotherapy. (A) Correlogram showing the association between MethScore with T cell dysfunction and T cell exclusion signatures in TCGA LUAD cohort, as determined using the tumor immune dysfunction and evasion (TIDE) method. (B) Differential composition of immune cell populations in cell samples with high and low methionine activity. The methionine activity was computed in three scRNA-seq data of LUAD (EMTAB6149, GSE117570, and GSE127465). (C) Violin plots comparing the MethScore between patients who benefitted and did not benefit from immunotherapy in indicated ICB cohorts. (D) The fraction of patients with clinical response to ICB among indicated ICB cohorts between patients with high and low MethScore (as stratified by the median score). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. (E) Kaplan-Meier curve depicting the PFS of lung cancer patients with high and low MethScore in the indicated ICB cohort.